BB Biotech Net Income Over Time
| BION Stock | CHF 47.20 0.15 0.32% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out BB Biotech Performance and BB Biotech Correlation. BION |
Cross Equities Net Income Analysis
Compare BB Biotech AG and related stocks such as Idorsia, Tecan Group AG, and Kuros Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDIA | (335.1 M) | (335.1 M) | (335.1 M) | (335.1 M) | (335.1 M) | (335.1 M) | (335.1 M) | (14.3 M) | (386.4 M) | (494.6 M) | (445.1 M) | (634.6 M) | (827.9 M) | (297.9 M) | (263.8 M) | (237.4 M) | (249.3 M) |
| TECN | 33 M | 47.6 M | 42.2 M | 45.7 M | 40.2 M | 57.1 M | 54.5 M | 66.5 M | 70.7 M | 73.2 M | 103.7 M | 121.7 M | 121.1 M | 132.1 M | 67.7 M | 77.8 M | 62.3 M |
| KURN | (23.9 M) | (18.8 M) | (9.2 M) | (30.8 M) | (34 M) | 6.2 M | (19.7 M) | (16.5 M) | (11.7 M) | (11.3 M) | (11.5 M) | (7.5 M) | (14.6 M) | (13.7 M) | (3.7 M) | (4.3 M) | (4.5 M) |
| BSLN | (59 M) | (57.6 M) | (53 M) | (33 M) | (41.5 M) | (61.6 M) | (51.3 M) | (19.4 M) | (31.4 M) | (22.4 M) | (14.7 M) | (6.8 M) | 12.1 M | 10.5 M | 77.6 M | 89.2 M | 93.7 M |
| EVE | (23.2 M) | (22.5 M) | (16 M) | (15.7 M) | (21.4 M) | (31.9 M) | (36 M) | (39 M) | (29.2 M) | (21.6 M) | (29.9 M) | (41.3 M) | (43.4 M) | (105.2 M) | 1 M | 939.6 K | 986.6 K |
| SANN | (28.3 M) | (27.8 M) | (31.4 M) | (5.8 M) | (7.5 M) | 5.9 M | (35.4 M) | (51.5 M) | (54.2 M) | (19 M) | (67.7 M) | (55.5 M) | (71.1 M) | 54.8 M | (42 M) | (37.8 M) | (39.7 M) |
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | (2.3 M) | (148.8 K) | (18.6 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (62 M) | (54 M) | (48.6 M) | (46.2 M) |
| ADXN | (20.5 M) | (31.1 M) | (27 M) | (14.5 M) | (1.8 M) | (4.2 M) | (3.1 M) | (3.3 M) | (1.6 M) | (14.8 M) | (12.9 M) | (15.4 M) | (20.8 M) | (10.6 M) | 7.1 M | 8.1 M | 8.5 M |
| NWRN | (14.9 M) | (6.4 M) | (2.4 M) | (7.1 M) | (10.1 M) | (22.8 M) | (15.2 M) | (5.3 M) | (15 M) | (20.2 M) | (21 M) | (14.9 M) | (17.5 M) | (16.2 M) | 15.8 M | 18.2 M | 19.1 M |
BB Biotech AG and related stocks such as Idorsia, Tecan Group AG, and Kuros Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in BB Biotech AG financial statement analysis. It represents the amount of money remaining after all of BB Biotech AG operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| BB Biotech AG | BION |
| Classification | IT |
| Business Address | Seestrasse 16, Ksnacht, |
| Exchange | SIX Swiss Exchange |
CHF 47.2
Additional Tools for BION Stock Analysis
When running BB Biotech's price analysis, check to measure BB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BB Biotech is operating at the current time. Most of BB Biotech's value examination focuses on studying past and present price action to predict the probability of BB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BB Biotech's price. Additionally, you may evaluate how the addition of BB Biotech to your portfolios can decrease your overall portfolio volatility.